We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Fecal dipeptidyl peptidase-4 may be used as a ...
In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...
Study results have validated that five routinely measured clinical values reliably identified patients with type 2 diabetes who had significantly different A1c responses to two important classes of ...
DPP-4 exists as a membrane-bound form, widely expressed and enzymatically active on numerous cell types and different vascular beds... ...as well as a soluble form ...
MedPage Today on MSN
Amputation risk in diabetes drops with GLP-1 drugs, study suggests
Association driven by fewer major amputations ...
The results suggest that dipeptidyl peptidase-4 (DDP-4) inhibitors, which are widely prescribed in Germany, are not a cost-effective option despite lower drug pricing compared with empagliflozin.
Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D), use of ...
Hyperkalemia in type 2 diabetes occurred less often with GLP-1 receptor agonists in routine care than dipeptidyl peptidase-4 (DPP-4) inhibitors, a large observational study in Sweden showed. Over a ...
Across a broad swath of patients, short-term use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor appears to reduce the risk of major adverse cardiovascular events, most notably cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results